Related Experiment Video
Updated: Dec 27, 2025
10:03
Physiologic Patient Derived 3D Spheroids for Anti-neoplastic Drug Screening to Target Cancer Stem Cells
Published on: July 5, 2019
9.3K
Critical Factors Shaping Strategy Development of an Innovative Medicine in Oncology
Andriy Krendyukov1, Sreekanth Gattu2
1Apogenix AG, VP Global Head Medical Affairs, Im Neuenheimer Feld 584, 69120, Heidelberg, Germany. akrendyukov@gmx.de.
Pharmaceutical Medicine
|February 29, 2020
Summary
Developing innovative oncology drugs requires revised strategies due to high costs and risks. Value-based healthcare necessitates strategies grounded in scientific understanding and clinical evidence for successful commercialization.
Area of Science:
- Oncology
- Pharmaceutical Development
- Health Economics
Background:
- Innovative oncology medicinal products demand substantial investment, long development timelines, and face high failure risks in clinical trials.
- Budgetary constraints and the need to demonstrate value heighten the importance of effective development and commercialization strategies for oncology products.
Purpose of the Study:
- To examine the unique challenges and strategic differences in developing and commercializing innovative oncology products compared to other industries.
- To analyze how the shift towards value-based healthcare influences medicinal product strategy in oncology.
- To identify key elements for successful oncology product strategy, emphasizing scientific understanding and clinical evidence.
Main Methods:
- Review of existing literature on medicinal product strategy and value-based healthcare.
- Survey of industry representatives involved in oncology drug development and commercialization.
- Analysis of strategic differences between the oncology sector and other industries.
Main Results:
- Standard industry strategies require significant adaptation for the oncology field, spanning preclinical, clinical, and post-approval phases.
- Value-based healthcare mandates strategies deeply rooted in scientific disease understanding and product-specific clinical evidence.
- Successful oncology strategies must integrate scientific rigor with market access and value demonstration.
Conclusions:
- Medicinal product strategy in oncology is distinct due to high R&D costs, regulatory hurdles, and evolving healthcare economics.
- Adapting strategies to align with value-based healthcare principles is crucial for the successful development and commercialization of innovative oncology treatments.
- Future oncology strategies must prioritize a robust scientific foundation, comprehensive clinical evidence, and clear value proposition to navigate market complexities.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
02:49Cancer Therapies
9.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.7K
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
157
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though...
157
01:27Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
01:11Clinical Trials: Overview
4.4K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.4K